NCT07895498
A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
pustular drug eruption assessed
Timeframe: Day 56 ± 3 days
Arms and interventions
SOCP aloneActive comparator
Minocycline Face: Hypochlorous acid solution Face: Hydrocortisone Trunk: Triamcinolone Scalp: Clobetasol propionate Photoprotection: Broad-spectrum sunscreen
Ivermectin 200 mcg/kg orally weekly plus SOCPExperimental
Ivermectin 200mcg/kg orally weekly PLUS SOCP above as in Arm A
Drugs: Minocycline, Hypochlorous Acid, Hydrocortison cream, Triamcinolone (TAC) 0.1% cream, Clobetasol, Ivermectin
Other: Photoprotection
Sites
7 sites in 1 country